Part of Thermo Fisher Scientific
01 August 2011
We are pleased to announce that on July 18, 2011, Thermo Fisher Scientific acquired TREK Diagnostic Systems, a global provider of microbiology solutions, including blood culture, microorganism identification and antibiotic susceptibility testing products.
The addition of VersaTREK® platforms to its microbiology portfolio allows Thermo Fisher to offer automated systems for blood culture and the detection of mycobacteria for the first time. VersaTREK complements the company’s manual blood culture systems, to provide the most comprehensive choice of tests and culture media for use in the diagnosis of sepsis and tuberculosis.
TREK’s other major brand, Sensititre, extends Thermo Fisher’s range of manual susceptibility testing and identification products that provide microbiologists with a range of tools to determine the resistance status of a microorganism.
“This acquisition is an important step in our strategy to bring a greater choice of workflow solutions to microbiologists worldwide,” said Andrew Carr, President, Microbiology, Thermo Fisher Scientific. “TREK is an ideal complement to our existing capabilities, allowing us to offer comprehensive solutions to aid in the diagnosis of sepsis. We can now provide easier access to technology used in the setting of global standards in antimicrobial susceptibility testing, for targeted antibiotic therapy and promotion of good antibiotic stewardship. And we will now offer a fully automated alternative for mycobacterial detection and resistance, crucial to the diagnosis of tuberculosis. Additionally, TREK has a significant product development pipeline that will be enhanced by the expertise and resources of Thermo Fisher Scientific.”
Trek products now join the industry-leading Thermo Scientific portfolio; a portfolio that is relied on for its quality, accuracy, reliability and innovation and that also encompasses the Oxoid and Remel brands which, like TREK, have a strong heritage in microbiology.